5-(4-氯苯基)-2-甲酰基-3--呋喃乙酯 | 175276-64-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-(4-氯苯基)-2-甲酰基-3--呋喃乙酯
• 英文名称: 5-(4-chlorophenyl)-2-formylfuran-3-carboxylic acid ethyl ester
• 英文别名: 3-ethoxycarbonyl-5-(4-chlorophenyl)furan-2-carboxaldehyde；ethyl 5-(4-chlorophenyl)-2-formyl-3-furoate；ethyl 5-(4-chlorophenyl)-2-formylfuran-3-carboxylate
• CAS: 175276-64-9
• 化学式: C₁₄H₁₁ClO₄
• 分子量: 278.692
• InChiKey: XFOQMTOCKSVCBO-UHFFFAOYSA-N

物化性质

• 熔点：
  188 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932190090

SDS

Name:	Ethyl 5-(4-chlorophenyl)-2-formyl-3-furoate 97% Material Safety Data Sheet
Synonym:	Ethyl-2-carboxaldehyde-5-(4-chlorophenyl)-3-furoat
CAS:	175276-64-9

Section 1 - Chemical Product MSDS Name:Ethyl 5-(4-chlorophenyl)-2-formyl-3-furoate 97% Material Safety Data Sheet
Synonym:Ethyl-2-carboxaldehyde-5-(4-chlorophenyl)-3-furoat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175276-64-9	Ethyl 5-(4-chlorophenyl)-2-formyl-3-fu	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175276-64-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 179 - 182 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H11ClO4
Molecular Weight: 279

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175276-64-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 5-(4-chlorophenyl)-2-formyl-3-furoate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 175276-64-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175276-64-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175276-64-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4-氯苯基)-2-甲酰基-3--呋喃乙酯 在 aluminum oxide 、 N-溴代丁二酰亚胺(NBS) 、 碘苯二乙酸 、 potassium tert-butylate 、 二异丁基氢化铝 、 potassium carbonate 、 caesium carbonate 、 溶剂黄146 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 9-(4-Chlorophenyl)-16-piperazin-1-yl-8,13-dioxa-2,5-diazatetracyclo[12.4.0.02,6.07,11]octadeca-1(14),3,5,7(11),9,15,17-heptaene
  参考文献：
  名称：

  Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors

  摘要：

  Facile synthesis of two new series of tetracyclic azepine and oxazocine analogs is described. These analogs were evaluated for their potential as MAPKAP-K2 (MK2) inhibitors and several were found to be potent at inhibiting MK2 with a non-ATP competitive binding mode. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.113

文献信息

• Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
  申请人：——

  公开号：US20020143026A1

  公开（公告）日：2002-10-03

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.

  本发明提供了I式化合物及其药用可接受的盐。公式I化合物诱导有丝分裂停滞，因此使它们可用作抗癌剂。公式I化合物还可用于治疗其他可以通过诱导有丝分裂停滞来治疗的疾病。
• Rigidified Compounds for Modulating Heparanase Activity
  申请人：Gelder M. Van Joel

  公开号：US20080039456A1

  公开（公告）日：2008-02-14

  Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.

  揭示了一种新颖的刚性化合物，其具有类似罗丹啉的残基和至少一个连接到类似罗丹啉残基的芳基或杂芳基残基，其中这些化合物的核心结构，如规范中定义的那样，其特征是具有一个或零个可自由旋转的键。还披露了含有这些刚性化合物的药物组合物以及用于调节肝素酶活性的用途，从而治疗与肝素酶相关的疾病和紊乱，并用于调节肝素结合蛋白的活性以及治疗与肝素结合蛋白相关的疾病和紊乱，以及治疗至少部分可通过罗丹啉或罗丹啉类似物治疗的医疗状况的用途。
• Fragment evolution for GPCRs: the role of secondary binding sites in optimization
  作者：Florent Chevillard、Ádám Kelemen、Jillian G. Baker、Vivien A. Aranyodi、Frank Balzer、Peter Kolb、György M. Keserű

  DOI：10.1039/d1cc04636e

  日期：——

  We developed a docking-based fragment evolution approach that extends orthosteric fragments towards a less conserved secondary binding pocket of GPCRs. Evaluating 13 000 extensions for the β1- and β2-adrenergic receptors we synthesized and tested 112 bitopic molecules. Our results confirmed the positive contribution of the secondary binding pocket to both potency and selectivity optimizations.

  我们开发了一种基于对接的片段进化方法，将正构片段扩展到不太保守的 GPCR 二级结合口袋。我们合成并测试了 112 个双位分子，评估了 13 000 次 β 1 - 和 β 2 -肾上腺素能受体的延伸。我们的结果证实了二级结合口袋对效力和选择性优化的积极贡献。
• Pyrimidones with antiviral properties
  申请人：Axxima Pharmaceuticals Aktiengesellschaft

  公开号：EP1389461A1

  公开（公告）日：2004-02-18

  The present invention relates to vinylpyrimidine-2-one derivatives of the general formula (I): Furthermore the present invention relates to vinylpyrimidine-2-one derivatives and of the general formula (Ia): wherein R1 to R6 in formula (I) and in formula (Ia) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties. The compounds are used as antivirals, especially against herpes and HCMV (Human Cytomegalovirus).

  本发明涉及一般式(I)的乙烯基嘧啶-2-酮衍生物，以及一般式(Ia)的乙烯基嘧啶-2-酮衍生物，其中在式(I)和式(Ia)中，R1至R6独立地表示各种不同的取代基，包括烷基，芳基，芳基烷基，烷基芳基，杂环芳基和单官能团。该化合物可用作抗病毒药物，特别是用于抗疱疹病毒和人类巨细胞病毒(HCMV)。
• [EN] CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES<br/>[FR] COMPOSES DE DIHYDROPYRIMIDINE CYANO-SUBSTITUES ET LEUR UTILISATION POUR TRAITER DES MALADIES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002079169A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I), formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.

  本发明提供了式(I)的化合物，式(I)和其药学上可接受的盐。式(I)化合物能够诱导有丝分裂停滞，因此它们可用作抗癌剂。式(I)化合物还可用于治疗其他可以通过诱导有丝分裂停滞来治疗的疾病。